Arusha Bavare, MD
Geriatric Medicine · Sugar Land, TXNPI 1730127770
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $453 and has fallen 58.2% since, to $189 in 2025.
Across 72 payments — averaging $26.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$298
- Silk Road Medical, Inc.$183
- Pfizer$176
- Johnson & Johnson$172
- Sunovion Pharmaceuticals Inc.$102
- AstraZeneca$98
- plus $880 from 25 others
What the payments were for
- Food & beverage$1,908100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $298 |
| Silk Road Medical, Inc. | 1 | $183 |
| Pfizer | 7 | $176 |
| Johnson & Johnson | 6 | $172 |
| Sunovion Pharmaceuticals Inc. | 7 | $102 |
| AstraZeneca | 5 | $98 |
| Pulmonx Corporation | 1 | $92 |
| Sumitomo Pharma America, Inc. | 4 | $75 |
| Lundbeck LLC | 3 | $62 |
| Axonics, Inc. | 2 | $61 |
| Merck | 3 | $59 |
| Bayer | 2 | $55 |
| Eisai Inc. | 2 | $54 |
| Boston Scientific | 2 | $45 |
| Smith+Nephew | 3 | $42 |
| Abbott | 2 | $38 |
| AbbVie(2 entities) | 2 | $33 |
| Biotronik NRO, Inc. | 1 | $32 |
| E.r. Squibb & Sons, L.L.C. | 2 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Corium, LLC | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
| Philips North America LLC | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,908 in reported general payments places this provider in the 85th percentile of 275 geriatric medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 578 | $207,873 |
| XareltoRivaroxaban | 112 | $46,938 |
| OzempicSemaglutide | 27 | $36,596 |
| MyrbetriqMirabegron | 81 | $24,291 |
| NamzaricMemantine Hcl/Donepezil Hcl | 29 | $17,563 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $15,615 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $14,876 |
| JardianceEmpagliflozin | 34 | $13,912 |
| TradjentaLinagliptin | 49 | $13,753 |
| JanuviaSitagliptin Phosphate | 27 | $13,456 |
| Atorvastatin Calcium | 1,009 | $12,490 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $12,054 |
| FarxigaDapagliflozin Propanediol | 22 | $11,234 |
| Pantoprazole Sodium | 322 | $11,226 |
| EntrestoSacubitril/Valsartan | 25 | $10,683 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $176 | $207,873578 claims |
| Johnson & JohnsonXarelto | $172 | $46,938112 claims |
| MerckJanumet, Januvia, Janumet Xr | $59 | $40,38651 claims |
| Astellas Pharma US IncMyrbetriq | $12 | $24,29181 claims |
| AbbVieNamzaric, Restasis | $33 | $23,76747 claims |
| AstraZenecaFarxiga, Brilinta | $98 | $17,19541 claims |
| NovartisEntresto | $14 | $10,68325 claims |
| Smith+NephewSantyl | $42 | $7,03314 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $75 | $5,63022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 275 geriatric medicine providers in Texas.
Other geriatric medicine in Sugar Land
- Ranganath KandalaSugar Land$5K
- Owen CapocyanSugar Land$1K
- Mauricio Gonzalez-AriasAustin$825K
- Eberenne IgbokwePearland$124K
- Diana KerwinDallas$81K
- David SmithBrownwood$19K
- Alejandro ArizmendiHelotes$15K
- Rosa VizcarraSan Antonio$9K
- George TaffetHouston$9K
- John CarrollCorpus Christi$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.